Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3.
黄山市人民医院 三甲 根据PD-L1+IHC检测结果,综合阳性评分(CPS)为10,PD-L1(Negative)为阴性,说明免疫治疗效果还可以。但需要注意以下几点:1.阴性表示效果可能不太好,但并非绝 患者:pd-l1+IHC检测结果:综合阳性评分(CPS):10,P 医生:明白了 查看更多医患对话 hpv阳性是什么意思?怎么回事?严重吗? 问hpv是什么及...
根据PD-L1+IHC检测结果,综合阳性评分(CPS)为10,PD-L1(Negative)为阴性,说明免疫治疗效果还可以。但需要注意以下几点:1.阴性表示效果可能不太好,但并非绝 患者:pd-l1+IHC检测结果:综合阳性评分(CPS):10,P 医生:明白了 查看更多医患对话 G-6PD是检查什么的 薛飞主治医师 枣庄矿业集团中心医院 三甲 G-6PD是葡...
Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3....
Do KH, Nguyen TV, Nguyen Thi Bich P, etc. Successful first-line pembrolizumab combined with chemotherapy in PD-L1-negative non-small cell lung cancer with a rare BRAF mutation: a case report and review of the literature [J]. Case reports in Respirology, 2023, 11(6): e01155 . ...
如果在传统的放化疗时，偶尔来这么一两个疗程，说不定会有奇效。参考文献：Iwata T ,et al., Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1. J Thorac Oncol. 2017 Dec;12(12):e205-e207.
Kien Hung Do et al, PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature, Respirol Case Rep. 2023 May 3....
如果在传统的放化疗时,偶尔来这么一两个疗程,说不定会有奇效。 参考文献: Iwata T ,et al., Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1. J Thorac Oncol. 2017 Dec;12(12):e205-e207....
PD-L1低表达组(negative):PD-L1<1% 研究结果 临床特征与PD-L1表达量及ICI疗效的关系: 年龄、性别、吸烟史和PD-L1的表达量无关; 取样方式和PD-L1表达量相关:手术切除肺部肿瘤组织取样,检测到PD-L1低表达患者多,而活检取样检测到PD-L1高表达患者更多; ...
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma. Clin Cancer Res. 2016; 22:3915-3923.Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA...